Goldman Sachs Downgrades 10x Genomics to Sell, Lowers Price Target to $35
Goldman Sachs analyst Matthew Sykes downgrades 10x Genomics (NASDAQ:TXG) from Neutral to Sell and lowers the price target from $55 to $35.
What 4 Analyst Ratings Have To Say About 10x Genomics
Within the last quarter, 10x Genomics (NASDAQ:TXG) has observed the following analyst ratings:
Why Bank Stocks Traded Sharply Higher; Here’s 65 Biggest Movers From Friday
Gainers
United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday.
Barron’s Stock Spotlight: Spirit Airlines, Rivian, UnitedHealth And This Genomics Company
Benzinga reviews this weekend's top stories on Barron's, for additional information on the latest market news, Benzinga Pro offers a 24/7 news feed, live chat and charting software.
What 5 Analyst Ratings Have To Say About 10x Genomics
Within the last quarter, 10x Genomics (NASDAQ:TXG) has observed the following analyst ratings:
Why This 10X Genomics Analyst Is Turning Bearish, Slashing Price Target
10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenues Thursday that were meaningfully below the consensus estimates.
Cowen & Co. Maintains Outperform on 10x Genomics, Lowers Price Target to $50
Cowen & Co. analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Outperform and lowers the price target from $90 to $50.
B of A Securities Downgrades 10x Genomics to Underperform, Lowers Price Target to $35
B of A Securities analyst Derik De Bruin downgrades 10x Genomics (NASDAQ:TXG) from Neutral to Underperform and lowers the price target from $80 to $35.